HRP20140044T1 - 4- [2- (4-methylphenylsulfanyl) phenyl]piperidine for the treatment of irritable bowel syndrome (ibs) - Google Patents

4- [2- (4-methylphenylsulfanyl) phenyl]piperidine for the treatment of irritable bowel syndrome (ibs) Download PDF

Info

Publication number
HRP20140044T1
HRP20140044T1 HRP20140044AT HRP20140044T HRP20140044T1 HR P20140044 T1 HRP20140044 T1 HR P20140044T1 HR P20140044A T HRP20140044A T HR P20140044AT HR P20140044 T HRP20140044 T HR P20140044T HR P20140044 T1 HRP20140044 T1 HR P20140044T1
Authority
HR
Croatia
Prior art keywords
compound
methylphenylsulfanyl
piperidine
phenyl
treatment
Prior art date
Application number
HRP20140044AT
Other languages
Croatian (hr)
Inventor
Silke Miller
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/DK2007/050076 external-priority patent/WO2007144006A1/en
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Publication of HRP20140044T1 publication Critical patent/HRP20140044T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Claims (6)

1. 4-[2-(4-metilfenilsulfanil)phenil]piperidin ili njegova farmaceutski prihvatljiva sol (spoj I) za uporabu u liječenju iritabilnog sindroma crijeva.1. 4-[2-(4-methylphenylsulfanyl)phenyl]piperidine or a pharmaceutically acceptable salt thereof (compound I) for use in the treatment of irritable bowel syndrome. 2. Spoj I prema zahtjevu 1, gdje se spoj I primjenjuje u kristalnom obliku. 2. Compound I according to claim 1, where compound I is applied in crystalline form. 3. Spoj I prema zahtjevu 2, gdje je spoj I adicijska sol bromovodika (HBr).3. Compound I according to claim 2, where compound I is an addition salt of hydrogen bromide (HBr). 4. Spoj I prema zahtjevu 2, gdje je HBr adicijska sol naznačena pikovima u rendgenskoj difrakciji praška (XRPD) na oko 6.08, 14.81, 19.26 i 25.38°2θ (sve ±0.1°).4. Compound I according to claim 2, wherein the HBr addition salt is indicated by X-ray powder diffraction (XRPD) peaks at about 6.08, 14.81, 19.26 and 25.38°2θ (all ±0.1°). 5. Spoj I prema zahtjevu 4, gdje je ta HBr adicijska sol naznačena rendgenskom difrakcijom praška (XRPD) kako je prikazano na Slici 1.5. Compound I according to claim 4, wherein said HBr addition salt is characterized by X-ray powder diffraction (XRPD) as shown in Figure 1. 6. Spoj I prema bilo kojem od zahtjeva 1-5, gdje se spoj I primjenjuje u dozi od 1-20 mg/dan.6. Compound I according to any one of claims 1-5, wherein compound I is administered at a dose of 1-20 mg/day.
HRP20140044AT 2007-06-15 2014-01-15 4- [2- (4-methylphenylsulfanyl) phenyl]piperidine for the treatment of irritable bowel syndrome (ibs) HRP20140044T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/DK2007/050076 WO2007144006A1 (en) 2006-06-16 2007-06-15 Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
PCT/DK2008/000216 WO2008151632A1 (en) 2007-06-15 2008-06-13 4- [2- (4-methylphenylsulfanyl) phenyl] piperidine for the treatment of irritable bowel syndrome (ibs)

Publications (1)

Publication Number Publication Date
HRP20140044T1 true HRP20140044T1 (en) 2014-02-14

Family

ID=39755623

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20140044AT HRP20140044T1 (en) 2007-06-15 2014-01-15 4- [2- (4-methylphenylsulfanyl) phenyl]piperidine for the treatment of irritable bowel syndrome (ibs)

Country Status (4)

Country Link
JP (1) JP5764327B2 (en)
HR (1) HRP20140044T1 (en)
SI (1) SI2167085T1 (en)
WO (1) WO2008151632A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200938194A (en) * 2007-12-14 2009-09-16 Lundbeck & Co As H Therapeutic uses of compounds having affinity to the serotonin transporter, serotonin receptors and noradrenalin transporter

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA81749C2 (en) * 2001-10-04 2008-02-11 Х. Луннбек А/С Derivated of phenylpiperazine as serotonin reuptake inhibitorS
PL2044020T3 (en) 2006-06-16 2011-09-30 H Lundbeck As Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl]piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
TWI432194B (en) * 2007-03-20 2014-04-01 Lundbeck & Co As H Novel therapeutic uses of 4-[2-(4-methylphenylsulfanyl)-phenyl]piperidine
TWI405588B (en) * 2007-03-20 2013-08-21 Lundbeck & Co As H Liquid formulations of salts of 4-[2-(4-methylphenylsulfanyl)-phenyl]piperidine

Also Published As

Publication number Publication date
WO2008151632A1 (en) 2008-12-18
JP2010529968A (en) 2010-09-02
SI2167085T1 (en) 2014-05-30
JP5764327B2 (en) 2015-08-19

Similar Documents

Publication Publication Date Title
JP2006298933A5 (en)
MY161903A (en) Substituted piperidines as ccr3 antagonists
ATE520406T1 (en) CRYSTALLINE FORM OF IBANDRONATE SODIUM
IN2012DN02465A (en)
JP2007302689A5 (en)
HRP20151299T1 (en) Crystalline (r) - (e) -2- (4- (2- (5- (1- (3, 5 -dichloropyridin-4 -yl) ethoxy) - 1h - indazol - 3 - yl) vinyl) -1 h- pyrazol- 1 -yl) ethanol and its use as fgfr inhibitor
WO2008046758A3 (en) Imidazolone and imidazolidinone derivatives as 11b-hsd1 inhibitors for diabetes
JP2010077141A5 (en)
DE602006021539D1 (en) Morpholine als 5ht2c-agonisten
HK1167607A1 (en) Quinoline derivative-containing pharmaceutical composition
JP2011527331A5 (en)
JP2012502037A5 (en)
JP2010536766A5 (en)
WO2007130438A3 (en) Solid dosage formulations
JP2013507408A5 (en)
WO2009016498A8 (en) Pyrimidine and pyridine derivatives and their pharmaceutical use and compositions
MY151295A (en) Pyrimidyl indoline compound
HRP20130049T1 (en) 4-[2-(4-methylphenylsulfanyl)phenyl]piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of adhd, melancholia, treatment resistent depression or residual symptoms in depression
NO20091185L (en) piperidine
JP2015509075A5 (en)
IL212230A (en) Crystalline form of a hydrochloric salt of 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound, process for its preparation, pharmaceutical compositions comprising same and uses thereof
JP2012508256A5 (en)
UA89905C2 (en) α-CRYSTALLINE FORM OF PERINDOPRIL ARGININE SALT, METHOD FOR MAKING SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
HRP20201217T1 (en) Derivatives of di(phenylpropanoid) glycerol for the treatment of cancer
MY161749A (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use